SWOG clinical trial number
S1011
A Phase III Surgical Trial to Evaluate The Benefit Of A Standard Versus An Extended Pelvic Lymphadenectomy Performed At Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer
Closed
Phase
Accrual
100%
Abbreviated Title
Muscle-Invasive Bladder Ca, Std vs Ext PLND, Ph III
Activated
08/01/2011
Closed
04/15/2017
Participants
Limited: Credentialed Surgeons Listed on S1011 Abstract Page
Research committees
Genitourinary Cancer
Treatment
Surgery
Eligibility Criteria Expand/Collapse
Pts must have histologically-proven T2, T3 or T4a bladder ca requiring radical cystectomy. Pt must not have clinical stage consistent with low-risk of node mets (CIS only, T1) nor T4b (fixed lesion). Pts with predominantly small cell, squamous cell, or adenocarcinoma histologies are not eligible. There must be plans for cystectomy and LND w/in 28 days of registration by study-specific credentialed surgeon. Laparoscopic surgery is not allowed. No prior partial cystectomy for invasive bladder ca. Pts must not have received any prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g. aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised. Prior neoadj chemo ok if completed w/in 70 days prior to planned cystectomy and pt recovered from associated toxicities. No prior pelvic irradiation. No evidence of visceral or nodal mets proximal to common iliac bifurcation on CXR or CT of abd and abd/pelvic CT or MRI w/in 56 days prior to reg. Bili, SGOT, SGPT, alk phos w/in IULN w/in 28 days prior to reg. These lab values may be greater than IULN if met dx excluded w/appropriate imaging. Prestudy physical exam & med hx w/in 28 days prior to reg. Pt must be offered specimen banking. Pt must have Zubrod PS of 0-2 and be medically suitable for cystectomy. Pt must not be pregnant or nursing at the time of radical cystectomy and women must have agreed to use effective contraceptive method. No other prior malignancy as outlined in 5.3e.
Publication Information Expand/Collapse
2024
2023
2019
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase